#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Superficial vein thrombosis Malignant central nervous system neoplasm Anaemia Glomerulonephritis rapidly progressive Immune-mediated myasthenia gravis Ichthyosis Familial hypertriglyceridaemia Huntington's disease Hyperinsulinism Obesity Glomerulonephritis acute Angiosarcoma non-metastatic Hypergammaglobulinaemia benign monoclonal Pulmonary arterial hypertension Cutaneous T-cell lymphoma More trials…

    Learn about Rare Diseases

    Ehlers-Danlos syndrome Lysosomal storage disorder – Trials in Disease Hypereosinophilic syndrome – Treatment Pemphigoid – Diagnostics Krabbe’s disease – Trials in Disease Hereditary hypophosphataemic rickets – Treatment Vascular malformation – Basic Information Hereditary angioedema – Treatment Leiomyosarcoma recurrent – Treatment SAPHO syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Azd8205 Mb-Cart20.1 Ampicillin Prasugrel Thiamine Hydrochloride Mk-1088 Vemurafenib Anhydrous Cholestyramine OMECAMTIV MECARBIL Rezafungin Acetate RP3 Cd7-Cart01 YOHIMBINE HYDROCHLORIDE Acetazolamide Sodium Loperamide Amantadine Hydrochloride Avalotcagene Ontaparvovec Palmidrol SP16 Dasatinib More therapies…

    Learn about Your Condition

    Implantation complication Inclusion body myositis End stage renal disease Nasopharyngeal cancer Retinal neovascularisation Chronic hepatic failure Eye inflammation IgA nephropathy Osteopenia Lymphoedema Medulloblastoma recurrent Type 2 diabetes mellitus Lennox-Gastaut syndrome Cutibacterium acnes infection Anxiety More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Theageneio Cancer Hospital

Theageneio Cancer Hospital

Simeonidi Alex 2, Thessaloniki, 546 39, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Daratumumab
    Austria Belgium Czechia Denmark Finland France +6

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of lung
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala
    • Mps-102
    • Mps-103
    Belgium France Germany Greece Hungary Italy +5

  • Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Olanzapine
    • Ondansetron
    • Selinexor
    Greece

  • Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Carfilzomib
    Belgium Croatia Czechia Denmark Finland France +10

  • Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Belantamab Mafodotin
    • Dexamethasone Sodium Phosphate
    • Bortezomib
    Belgium Czechia France Germany Greece Italy +3

  • Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Lenalidomide
    • Teclistamab
    Austria Belgium Czechia Denmark France Germany +7

  • Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Adenocarcinoma of colon
    Investigated Drugs:
    • Dostarlimab
    • Capecitabine
    • Fluorouracil
    Belgium Czechia Estonia Finland France Germany +8

  • Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Dexamethasone Sodium Phosphate
    • Diphenhydramine
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    Austria Germany Greece Italy The Netherlands

  • Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • Piflufolastat (18F)
    • Gozetotide
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Austria Belgium Czechia France Germany Greece +5

  • Study on Optimizing CDK 4/6 Inhibitors and Endocrine Therapy for Older Patients with Advanced Breast Cancer Using Abemaciclib, Palbociclib, and Ribociclib

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Exemestane
    Finland Greece Italy Norway Spain Sweden
Previous Page
1 2 3 4 5 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!